°®¶¹´«Ã½

December 11, 2018

The result of the Access to Medicine Index (ATM Index) 2018 was announced and Eisai has been ranked 8th among the world’s leading pharmaceutical companies. Eisai has risen three places in the rankings from 11th in both 2014 and 2016.

This Index is compiled by the Access to Medicine Foundation (the Foundation), an international non-profit organization dedicated to improving access to medicine for patients in need. The ATM Index has been published by the Foundation every two years since 2008. Based on publicly disclosed information and individual surveys, the ATM Index independently evaluates companies’ efforts to improve access to medicine for diseases and countries designated by the Index to rank the world’s top 20 pharmaceutical companies leading in initiatives for access to medicine issues in developing and emerging countries.

In the ATM Index 2018 report, Eisai’s continued commitment to combat neglected tropical diseases (NTDs) was selected as best practice. Furthermore, the Foundation highlighted Eisai’s efforts to accelerate research and development of new treatments for NTDs, malaria and tuberculosis by leveraging partnerships with various stakeholders including governments, international organizations, academia and non-profit private sector organizations.

Aiming to eliminate lymphatic filariasis (LF), an NTD, Eisai has been providing diethylcarbamazine citrate (DEC) tablets free of charge to endemic countries in collaboration with the World Health Organization (WHO) starting from 2013, and Eisai has provided more than 1.5 billion DEC tablets to 28 countries¹ (as of November 2018). Eisai has declared that it will continue the stable supply of high quality DEC tablets until the disease is eliminated in all LF endemic countries that need DEC tablets.

Under its hhc philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries. Once they have recovered their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. By implementing activities to improve access to medicines including raising disease awareness locally and implementing price setting models that take income levels into account in addition to the supply of DEC tablets as well as research and development of new treatments, Eisai strives to further contribute to increasing the benefits for patients and their families worldwide.

Please refer to the following link for details of the ATM Index 2018 results:
 

• ¹
  American Samoa, Comoros, Dominican Republic, Egypt, Eritrea, Fiji, French Polynesia, Guyana, Haiti, India, Indonesia, Kenya, Kiribati, Lao PDR, Madagascar, Malaysia, Micronesia (FSM), Myanmar, Papua New Guinea, the Philippines, Samoa, São Tomé and Príncipe, Sri Lanka, Thailand, Timor-Leste, Tuvalu, Zambia, Zimbabwe (alphabetical order)